Buy & Sell Regeneron Pharmaceuticals Inc (REGN) – Regeneron Pharmaceuticals Inc Price Today
Aura AI Summary
Key Stats
- $74.34BMarket Cap
- HealthSector
- -14.52%3M Drawdown
- $68.29BEnterprise Value
- 0.53%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 96 daysTypical Hold Time
Regeneron Pharmaceuticals Inc (REGN) is currently valued at a market capitalization of $74.34B, with an enterprise value of $68.29B. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $483.07 and a high of $812.27, highlighting its annual price range. Over the past three months, Regeneron Pharmaceuticals Inc has recorded a drawdown of -14.52%, reflecting recent price volatility. Regeneron Pharmaceuticals Inc offers a dividend yield of 0.53%, with the most recent dividend of $0.94 paid on 20 Feb 26. On average, investors hold Regeneron Pharmaceuticals Inc for approximately 96 days, indicating typical investor behavior on the platform.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Most Recent News
Wrap Technologies to showcase non-lethal BolaWrap system at European law enforcement event in Italy
Wrap Technologies will present its non-lethal BolaWrap device, immersive WrapReality training, and policy strategies at a European law enforcement conference in Italy on May 13-14, 2026. The event aims to introduce safer, modern public safety tools t...
FDA agrees on two clearance pathways for BioCardia's Helix delivery catheter, favoring simultaneous CardiAMP therapy approval.
BioCardia announced that the FDA agreed on two possible marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no safety or performance concerns raised. The FDA's preferred approval route is simultaneous with the C...
US Treasury may borrow over $2 trillion in fiscal 2026 amid rising debt and costs.
The US Treasury plans to borrow more than $2 trillion from private markets in fiscal year 2026, driven by a projected $2.065 trillion deficit and rising national debt nearing $39 trillion. Borrowing needs are expected to stay above $2 trillion throug...
